#US Acute Myeloid Leukemia Market Future Outlook | Explore Tumblr posts and blogs

kenresearch1 · 1 year ago

Text

The Transformative Growth of the US Acute Myeloid Leukemia Market

Buy Now

What is the Size of US Acute Myeloid Leukemia Industry?

US Acute Myeloid Leukemia Market is expected to grow at a CAGR of ~ % in 2022 and is expected to reach ~USD Mn by 2028. The US Acute Myeloid Leukemia market is the rapid advancement in precision medicine and targeted therapies. The emergence of innovative treatments tailored to the genetic and molecular characteristics of individual AML patients has transformed the treatment landscape. Targeted therapies, such as FLT3 and IDH inhibitors, capitalize on specific genetic mutations driving AML, resulting in higher response rates and improved outcomes compared to traditional approaches.

Precision medicine's ability to identify the most effective treatment for each patient not only enhances therapeutic efficacy but also reduces unnecessary treatments, mitigating side effects and improving overall quality of life. This paradigm shift is bolstered by technological progress in molecular profiling techniques like next-generation sequencing, allowing for accurate genetic profiling and treatment customization.

Furthermore, regulatory support and accelerated approval pathways for targeted therapies have expedited their availability to patients. Pharmaceutical companies' increasing investment in research and development of novel agents, along with collaborations between academia and industry, leads to grow this market even more.

Click here to Download a Sample Report

US Acute Myeloid Leukemia Market by treatment type

The market is segmented by Treatment type into Chemotherapy, Targeted Therapy, Hormone Therapy, Immunotherapy and Others. Targeted Therapy is the dominant segment in the US Acute Myeloid Leukemia market in 2022. Specialty Centers, dedicated to the diagnosis, treatment, and management of specific medical conditions like AML, offer a concentrated and specialized approach to patient care. Their dominance in the AML market is driven by their unique capabilities to provide comprehensive and tailored treatments that address the complex needs of AML patients.

US Acute Myeloid Leukemia Market by end -user industry

The market is segmented by End-User into Hospitals, Homecare, Specialty Centers, Pharmacies and Others. Among these, Specialty Centers are the dominant End-User in the US Acute Myeloid Leukemia market in 2022. Specialty centers have a higher level of expertise and experience in treating specific types of cancer, including acute leukemia. They typically have specialized medical professionals, including hematologists and oncologists, who are well-versed in the latest treatment protocols and research. These centers are equipped with state-of-the-art diagnostic and treatment facilities that are specifically tailored to the needs of leukemia patients. This can include advanced imaging technologies, specialized laboratories, and access to cutting-edge therapies.

Click here to Download a Custom Report

US Acute Myeloid Leukemia companies market by Region

The US Acute Myeloid Leukemia market is segmented by Region into North, South, East, West. The dominance region is North in the US Acute Myeloid Leukemia Market in 2022. the North region often benefits from a higher level of funding for medical research, including AML. Federal funding agencies, private foundations, and pharmaceutical companies frequently channel resources into institutions within this region, allowing for greater research capabilities and clinical trials infrastructure.

Competition Scenario in US Acute Myeloid Leukemia Market

The US acute myeloid leukemia market was characterized by the presence of several prominent pharmaceutical companies and biotechnology firms striving to establish their presence and gain a competitive edge.

Larger corporations, smaller biotechnology companies making significant contributions to the AML landscape. Companies like Agios Pharmaceuticals and Daiichi Sankyo were gaining attention for their novel therapies targeting AML-associated mutations. These players are often at the forefront of introducing precision medicine approaches to AML treatment, taking advantage of advancements in genetic profiling and molecular diagnostics.

The competition is further intensified by research collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations. These collaborations aimed to combine resources, expertise, and insights to accelerate the development of effective therapies.

What is the Expected Future Outlook for the Overall US Acute Myeloid Leukemia market?

The US Acute Myeloid Leukemia market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Million by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. Pharmaceutical companies have been actively researching and developing novel therapies for Acute Myeloid Leukemia, with a focus on improving patient outcomes and reducing the side effects associated with traditional treatments like chemotherapy. The approval of new drugs, such as FLT3 and IDH inhibitors, has offered fresh therapeutic avenues for specific subsets of Acute Myeloid Leukemia patients with genetic mutations.

The future outlook for the US Acute Myeloid Leukemia market is anticipated to be influenced by a combination of factors including advancements in treatment options, evolving regulatory landscapes, and a growing understanding of the molecular basis of Acute Myeloid Leukemia. The market has been witnessing a shift towards personalized medicine, with increasing emphasis on targeted therapies and precision medicine approaches.

Furthermore, the integration of innovative technologies like next-generation sequencing (NGS) has enhanced our understanding of Acute Myeloid Leukemia’s molecular complexities, allowing for better patient stratification and treatment selection. This trend toward molecular profiling and personalized treatment regimens is likely to continue shaping the market landscape.

However, challenges persist. Despite progress, Acute Myeloid Leukemia remains a difficult-to-treat disease with a high relapse rate. Overcoming drug resistance and developing effective strategies for patients who do not respond well to existing therapies remain critical areas of focus.

Additionally, the cost of novel therapies and access to these treatments could also impact their adoption and availability. The regulatory environment, including expedited pathways for drug approvals, continue to influence market dynamics.

0 notes

wellnessweb · 5 months ago

Text

Leukemia Therapeutics Market Size: Competitive Landscape Analysis

The Leukemia Therapeutics Market size was USD 16 Billion in 2023 and is expected to Reach USD 27.28 Billion by 2031 and grow at a CAGR of 6.9% over the forecast period of 2024-2031.The leukemia therapeutics market is experiencing rapid growth, driven by advancements in targeted therapies and personalized medicine. With an increasing understanding of the genetic and molecular mechanisms underlying various leukemia subtypes, pharmaceutical companies are developing innovative treatments that offer improved efficacy and reduced side effects. The market is also benefiting from a surge in research and development activities, coupled with supportive regulatory frameworks that expedite the approval process for novel drugs. Furthermore, the rise in leukemia prevalence, along with heightened awareness and early diagnosis, is expanding the patient pool eligible for these cutting-edge therapies. This dynamic landscape presents significant opportunities for stakeholders, ranging from biotech startups to established pharmaceutical giants, to make impactful contributions to leukemia care and patient outcomes.

Get Sample of This Report @ https://www.snsinsider.com/sample-request/3135

Market Scope & Overview

The market report gives thorough information to help readers comprehend the current situation of the industry. The report relied on primary and secondary research, as well as private databases and a paid data source. The market research report sheds light on the history and future of the Leukemia Therapeutics Market business. The report analyses the market size and includes information on market drivers, limitations, and opportunities.

The market research report examines the primary strategies used by top industry players to advance their operations in the worldwide market while maintaining a competitive advantage over their competitors. The Leukemia Therapeutics Market study also depicts the competitive landscape of the industry's major competitors, as well as the top organizations’ percentage market share.

Market Segmentation Analysis

By Type

Chronic Lymphocytic Leukemia

Acute Lymphocytic Leukemia

Chronic Myeloid Leukemia

Acute Myeloid Leukemia

Others

By Drug Class

Targeted Therapy

Chemotherapy and Immunotherapy

By Distribution channel

Hospital Pharmacies

Online Providers

Drug Store

Retail Pharmacies

COVID-19 Pandemic Impact Analysis

In this Leukemia Therapeutics Market analysis, the impact of COVID-19 on the market is analyzed at both the global and country levels. According to this analysis, the COVID-19 pandemic and the post-pandemic phase had a significant impact on both the supply and demand sides of the market.

Regional Outlook

The report's accurate data will help market participants make informed decisions about regional expansions and investments. The report looks at the dynamics of the Leukemia Therapeutics Market in relation to worldwide market conditions.

Competitive Analysis

The data in this section will assist readers in understanding the primary strategies used by leading market players to control the global Leukemia Therapeutics Market . The research report includes a PORTER, SVOR, and PESTEL analysis, as well as an examination of the potential impact of microeconomic market variables. External and internal elements that are projected to have an impact on the company have been studied, presenting decision-makers with a clear picture of the industry's future.

Key Questions Answered in the Leukemia Therapeutics Market Report

What is the forecasted growth rate, market share, and m market size?

Who are the market's dominant players, and how have they gained a competitive advantage over their competitors?

Conclusion

The Leukemia Therapeutics Market research report's estimations and estimates examine the impact of different political, social, and economic factors, as well as current market conditions, on market growth. All of this important information will assist the reader in better understanding the market.

About Us

SNS Insider is a market research and insights firm that has won several awards and earned a solid reputation for service and strategy. We are a strategic partner who can assist you in reframing issues and generating answers to the trickiest business difficulties. For greater consumer insight and client experiences, we leverage the power of experience and people.

When you employ our services, you will collaborate with qualified and experienced staff. We believe it is crucial to collaborate with our clients to ensure that each project is customized to meet their demands. Nobody knows your customers or community better than you do. Therefore, our team needs to ask the correct questions that appeal to your audience in order to collect the best information.

Related Reports

Protein Engineering Market Share

AI in Cancer Diagnosis Market Share

Blood Group Typing Market Share

Immunomodulators Market Share

Lymphoma Treatment Market Share

0 notes

kennethresearch · 3 years ago

Text

Global Asparaginase Market, June 2021 Report On Analysis 2021, Size, Top Players with Share, Total Revenues, Product Scope, Business Development and Opportunities till 2030

In a recently published report, Global Asparaginase Market report for till 2030. The report further now discusses; the various strategies to be adopted or being adopted by the business players across the globe at various levels in the value chain. In view of the global economic slowdown, we further estimated that China, India, Japan and South Korea to recover fastest amongst all the countries in the Asian market. Germany, France, Italy, Spain to take the worst hit and this hit is expected to regain 25% by the end of 2021- Positive Growth in the economic demand and supply.

U S Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analysis and U.S. Census Bureau mention the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) average exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilst imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Global Asparaginase Market products.

Get Sample Reports Here – https://www.kennethresearch.com/sample-request-10306407

It is also anticipated to grow on account of the growing demand for chemicals from the end users, backed by the increasing consumption of chemicals across different industries and the rising need for advanced chemicals. In India, the production of major chemicals and petrochemicals during the period 2020-2021 was close to 12000 thousand MT. Additionally, between the period 2015-16 and 2019-20, the production of the chemicals and petrochemicals in the nation grew at a CAGR of close to 6%.

Global Asparaginase Market is valued approximately at USD XXX million in 2018 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2019-2026. Asparaginase is an enzyme which catalzes the hydrolysis of l-asparagine to l-aspartic acid and ammonia. Asparaginase products are isolated from different types of bacteria, namely Escherichia coli and Erwinia chrysanthemi. They inhibit protein synthesis in tumor cells by depriving them of the amino acid asparagine. These are used widely in Healthcare industry and Food manufacturing industry as a medication. It is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin’s lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available. As Asparaginase was approved for medical use in the United States in 1978. It is also on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system. Asparaginase is used in the food manufacturing to reduce the formation of acrylamide. Acrylamide is a carcinogen in the starch containing food products such as biscuits and snacks. Thus, the rapidly growing healthcare and food manufacturing industry increase the demand for Asparaginase during the forecast period. As the Food and drinks market in Europe contributed to be the largest manufacturing sector in 2017 with a turnover of USD 1222 billion. The same sector invested USD 3.12 billion in research & development in 2017 which shows a positive sign in the market growth. Further, the rising investments of the market players for the research and development and production of Asparaginase according to the regulatory specification due to the rise in demand further fuels the market growth. However, the side effects of Asparaginase on human body such as mild bone marrow suppression, pancreatitis, anticoagulant factor resulting in stroke and bleeding hinders the market growth.

The regional analysis of global Asparaginase market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the dominant pharmaceutical industry in the region which is the major industry which uses Asparaginase enzyme. Further rising cases of Leukemia in the region propel the market growth. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2019-2026. Factors such as increasing population along with increasing disposable income coupled with growing food manufacturing industry would create lucrative growth prospects for the Asparaginase market across Asia-Pacific region.

Major market player included in this report are: Jazz Pharmaceuticals Plc Shire Plc Medac GmbH Kyowa Hakko Kirin Co., Ltd. Qianhong Bio-pharma Taj Pharmaceuticals Mingxing Pharma Exova SL Pharma Inc United Biotech Pvt. Ltd. Novus Biologicals The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below: By Type: Escherichia Coli Erwinia Chrysanthemi Pegylated By Application: Healthcare Food Industry Others By Region: North America U.S. Canada Europe UK Germany Asia Pacific China India Japan Latin America Brazil Mexico Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2016, 2017 Base year – 2018 Forecast period – 2019 to 2026

Target Audience of the Global Asparaginase Market in Market Study:

Key Consulting Companies & Advisors Large, medium-sized, and small enterprises Venture capitalists Value-Added Resellers (VARs) Third-party knowledge providers Investment bankers Investor

Download Sample Reports Here – https://www.kennethresearch.com/sample-request-10306407

The report further discusses the market opportunity, compound annual growth rate (CAGR) growth rate, competition, new technology innovations, market players analysis, government guidelines, export and import (EXIM) analysis, historical revenues, future forecasts etc. in the following regions and/or countries:

North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook

Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth Market Players Analys & Opportunity Outlook

Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Market Players Analysis & Opportunity Outlook

Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth Market Players Analysis & Opportunity Outlook

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Kenneth Research

Email : [email protected]

Phone: +1 313 462 0609

0 notes

newsbulletin · 4 years ago

Text

Global Platelet Aggregation Devices Market Trends, Industry Report 2027

New York, NY 14 May 2021: The global platelet aggregation devices market size is expected to reach USD 1,556.8 million by 2027 according to a new study by Polaris Market Research. The report “Platelet Aggregation Devices Market Share, Size, Trends, Industry Analysis Report, By Product (Systems, Reagents, Consumables and Accessories); By Application (Research Applications, Clinical Applications, Others); By End Use (Standalone Hospitals, Diagnostic Laboratories, Research and Academic Institutes, Blood Banks, and Other End Users); By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Platelet aggregation is the biological process where the platelet cells are employed in a process to prevent bleeding through vaso-constriction for rapid clot formation. The whole process is mediated via platelet aggregating factor (PAF). The quantitative and qualitative defects of platelets lead to increased bleeding. The high reactivity of platelets in the patients having anti-platelet therapy results in thromboembolic complications.

Platelet function related disorders can be either inherited or acquired. The inherited platelet function disorders include Von Willebrand disease, Glanzmann’s thrombasthenia, Bernard-Soulier syndrome, Storage pool disease. The acquired platelet dysfunction may be caused by chronic conditions such as kidney failure (uremia), Myelodysplastic syndrome (MDS), Leukemias (chronic myeloid leukemia or CML; acute myeloid leukemia or AML).

Some acquired platelet disorders are temporary because of the decreased function of platelets due to anti-platelet medications, non-steroidal anti-inflammatory drugs (NSAIDs), tricyclic antidepressants, antihistamines and some antibiotics. The platelet function testing is transitioned from diagnostics for heritable diseases to a functional one for platelet functional therapies. The rapid usage of anti-platelet therapy, mainly dual anti-platelet therapy has changed the focus of platelet function testing from diagnostics to therapeutics.

Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-sample

The market is driven by few notable factors such as the recent surge in infectious diseases (COVID-19) requiring rapid serological tests, innovations in platelet aggregation mechanisms, systems and consumables, and worldwide rise in chronic ailments. Specialized tests based on platelet aggregation include light transmission platelet aggregometry on platelet-rich plasma (LTA), impedance whole blood aggregometry (WBA), Lumi-aggregometry and flow cytometry.

Automated haematology analyzers can be used to obtain platelet counts over a wide range of values using optical counting methods like light scatter or fluorescence. Screening tests such as prothrombin time (PT) or activated partial thromboplastin time (aPTT) are more standardized and fully automated.

Number of reagents are available in the market to carry out the platelet function tests. These reagents include collagen, thrombin, ADP, vasopressin, epinephrine and ristocetin. Collagen, ADP were used in routine platelet aggregation studies for the evaluation of qualitative platelet function disorders.

Market participants such as F. Hoffmann La-Roche Ltd., Drucker Diagnostics, Haemonetics Corporation, Sysmex Corporation, Siemens Healthineers, Chrono-log Corporation, Instrumentation Laboratory, Accriva Diagnostics, Matis Medical, Helena Laboratories Corporation, Sienco, Inc., Bio/Data Corporation, Tem Group, WerfenLife, S.A., Laboratory Corporation of America Holdings, Sentinel CH. S.p.A., and Aggredyne, Inc. are some of the key players operating in the concerned market.

To get Incredible Discounts on this Premium Report, Click At: https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-discount-pricing

Polaris Market research has segmented the vascular access devices market report on the basis of product, application, end-use and region

Platelet Aggregation Devices Type Outlook (Revenue – USD Million, 2016 – 2027)

Systems

Reagents

Consumables and Accessories

Platelet Aggregation Devices Application Outlook (Revenue – USD Million, 2016 – 2027)

Research Applications

Clinical Applications

Others

Platelet Aggregation Devices End-Use Outlook (Revenue – USD Million, 2016 – 2027)

Standalone Hospitals

Diagnostic Laboratories

Research and Academic Institutes

Blood Banks

Other End Users

Have Any Query or Specific Requirement? Request for customization: https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-customization

About Polaris Market Research

Polaris Market Research

Phone: 1–646–568–9980

Email: [email protected]

Web: http://www.polarismarketresearch.com

#Platelet Aggregation Devices market Platelet Aggregation Devices Insight Platelet Aggregation Devices Growth Platelet Aggregation Devices si

0 notes

kunalcmi · 4 years ago

Text

INDIA IMMUNE-ONCOLOGY DRUGS MARKET ANALYSIS - (2018-2026)

Immuno-Oncology refers to the use of body’s natural defenses to fight disease. It works by stimulating the immune system instead of fighting the tumors, avoiding disturbance in functionality of healthy cells. Immuno-oncology drugs facilitates long-term response against cancer by providing long-lasting memory to the immune system. Immuno-Oncology drugs works against a wide variety of cancers, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine-based immunotherapy, cancer vaccines, and other therapies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah.

Market Dynamics

Increasing prevalence of cancer in India is expected to drive India Immune-Oncology Drugs Market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.

However, factors such as high-cost associated with immuno-oncology therapies makes it unaffordable for population in the low and middle-income class, to opt for these therapies, thus restraining growth of the market. For instance, Keytruda (Pembrolizumab), a monoclonal antibody for the treatment of various types of cancer costs around US$ 2,250 for a vial of 50 mg. Moreover, according to the World Health Organization (WHO), in February 2018, around 70% of deaths from cancer occur in low and middle-income countries. This can be attributed to high-prices of oncology therapies, which cannot be afforded by patients with low incomes.

Request Sample Free Copy of Report here: https://www.coherentmarketinsights.com/insight/request-sample/2631

Download PDF Brochure:https://www.coherentmarketinsights.com/insight/request-pdf/2631

Key features of the study:

This report provides in-depth analysis of the India Immune-Oncology Drugs Market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players

It profiles key players in the India immuno-oncology drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include Amgen, Inc., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology company, Reliance Life Sciences, Biocon Limited and Hetero Drugs Limited.

Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

India immuno-oncology drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for India immuno-oncology drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

India Immuno-Oncology Drugs Market, By Drug Type:

Immune Checkpoint Inhibitors

Nivolumab (Opdivo)

Atezolimumab (Tecentriq)

Pembrolizumab (Keytruda)

Durvalumab (Imfinzi)

Monoclonal Antibodies

Rituximab (Rituxan)

Trastazumab (Herceptin)

Bevacizumab (Avastin)

Nimotuzumab (Biomab EGFR)

Pertuzumab (Perjeta)

Ado-Trastuzumab Emtansine (Kadcyla)

Cancer Vaccines

Gardasil

Cervarix

India Immuno-Oncology Drugs Market, By Cancer Type:

Lung Cancer

Blood Cancer

Breast Cancer

Ovarian Cancer

Cervical Cancer

Colorectal Cancer

Stomach Cancer

Head & Neck Cancer

Others

Company Profiles

Amgen, Inc.*

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

Hoffmann-La Roche AG

Intas Pharmaceuticals Ltd.

AstraZeneca plc

Mylan N.V.

Reddy's Laboratories

Bristol - Myers Squibb

Merck & Co., Inc.

BIOCAD-Biotechnology company

Reliance Life Sciences

Biocon Limited

Hetero Drugs Limited

“*” marked represents similar segmentation in other categories in the respective section.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Explore CMI Services here

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: [email protected]

Source: https://www.coherentmarketinsights.com/market-insight/india-immune-oncology-drugs-market-2631

#India Immune-Oncology Drugs #CoherentMarketInsights #MarketResearch #Industryanalysis #BusinessConsulting

0 notes

udaycmi · 4 years ago

Link

The global platelet aggregation devices market size is expected to reach USD 1,556.8 million by 2027 according to a new study by Polaris Market Research. The report “Platelet Aggregation Devices Market Share, Size, Trends, Industry Analysis Report, By Product (Systems, Reagents, Consumables and Accessories); By Application (Research Applications, Clinical Applications, Others); By End Use (Standalone Hospitals, Diagnostic Laboratories, Research and Academic Institutes, Blood Banks, and Other End Users); By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Get Sample Copy of report: https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-sample

Polaris Market research has segmented the vascular access devices market report on the basis of region

Platelet Aggregation Devices Regional Outlook (Revenue – USD Million, 2016 – 2027)

North America

· U.S.

· Canada

Europe

· France

· Germany

· UK

· Italy

· Spain

· Netherlands

· Austria

Asia Pacific

· China

· India

· Japan

· Malaysia

· South Korea

· Indonesia

Central & South America

· Mexico

· Brazil

· Argentina

Middle East & Africa

· UAE

· Saudi Arabia

· Israel

· South Africa

Request Discount: https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Polaris Market Research

Phone: 1-646-568-9980

Email: [email protected]

Web: www.polarismarketresearch.com

0 notes

adwaitcoherent · 4 years ago

Text

By 2026, India Immune-Oncology Drugs Market To Surpass US$ 461.8 Million - Coherent Market Insights

India Immune-Oncology Drugs Market To exhibit a CAGR of 13.1% over the forecast period (2018 - 2026)

Request for Sample PDF Copy:

https://www.coherentmarketinsights.com/insight/request-pdf/2631

Description:

Market Dynamics

Increasing prevalence of cancer in India is expected to drive India Immuno-Oncology Drugs market growth. For instance, according to National Cancer Registry Programme (NCRP), India, one woman dies of cervical cancer every 8 minutes in India. For every 2 women newly diagnosed with breast cancer, one woman dies of it in India. Furthermore, as many as 2,500 persons die every day due to tobacco-related diseases in India. Tobacco (smoked and smokeless) use accounted for around 317,928 deaths in men and women in 2018.

Key features of the study:

This report provides in-depth analysis of the India immuno-oncology drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

Detailed Segmentation:

India Immuno-Oncology Drugs Market, By Drug Type:

Immune Checkpoint Inhibitors

Nivolumab (Opdivo)

Atezolimumab (Tecentriq)

Pembrolizumab (Keytruda)

Durvalumab (Imfinzi)

Monoclonal Antibodies

Rituximab (Rituxan)

Trastazumab (Herceptin)

Bevacizumab (Avastin)

Nimotuzumab (Biomab EGFR)

Pertuzumab (Perjeta)

Ado-Trastuzumab Emtansine (Kadcyla)

Cancer Vaccines

Gardasil

Cervarix

India Immuno-Oncology Drugs Market, By Cancer Type:

Lung Cancer

Blood Cancer

Breast Cancer

Ovarian Cancer

Cervical Cancer

Colorectal Cancer

Stomach Cancer

Head & Neck Cancer

Others

Company Profiles

Amgen, Inc.*

Company Overview

Product Portfolio

Financial Performance

Recent Highlights

Strategies

Hoffmann-La Roche AG

Intas Pharmaceuticals Ltd.

AstraZeneca plc

Mylan N.V.

Reddy's Laboratories

Bristol - Myers Squibb

Merck & Co., Inc.

BIOCAD-Biotechnology company

Reliance Life Sciences

Biocon Limited

Hetero Drugs Limited

“*” marked represents similar segmentation in other categories in the respective section.

About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.

Buy Report Here:

https://www.coherentmarketinsights.com/insight/buy-now/2631

Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave. #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

#Market Analysis #Market Research #Coherent Market Insights

0 notes

myabhijitr · 5 years ago

Text

Biologics Market Industry Growth, Size, Share, Outlook, and Forecast, 2018 to 2026

Biologics market size is expected to boost owing to the increasing product pipeline from different companies like Merck and Co., Pfizer, Glaxosmithkline. Pfizer has a strong product pipeline for 2019 of biologics, biosimilars, vaccines and small molecules. 35 products are in phase 1, 28 are in phase 2 and 26 are in phase 3 and 11 products are in the process of registration. Total 100 products are in trial phase. Most recent approval by Pfizer is DAURISMO (glasdegib) in U.S. for adult patients with newly-diagnosed acute myeloid leukemia for whom intensive chemotherapy is not an option.

Furthermore, the biologics market revenue is growing because of increasing number of Food and Drug Administration (FDA) approvals for new biologic medicines for treatment of rare diseases. For instance, in 2017 US FDA approved 46 biologics and in December 2017, GlaxoSmithKline’s biologic Nucala was approved for the treatment of a rare disease called eosinophilic granulomatosis, with polyangiitis (EPGA).

Key players operating in the global biologics market include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Merck KGaA, Novartis, Pfizer, F. Hoffmann-La Roche Ltd, and Sanofi.

Get Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2663

Important Features that are under offering & key highlights of the report :

1) Can we add or profiled new company as per our need? Yes, we can add or profile new company as per client need in the report. Final confirmation to be provided by research team depending upon the difficulty of survey.

** Data availability will be confirmed by research in case of privately held company. Upto 3 players can be added at no added cost.

2) What all regional segmentation covered? Can specific country of interest be added? Currently, research report gives special attention and focus on following regions: North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc), South America (Brazil, Argentina etc) & Middle East & Africa (Saudi Arabia, South Africa etc)

** One country of specific interest can be included at no added cost. For inclusion of more regional segment quote may vary.

3) Can inclusion of additional Segmentation / Market breakdown is possible? Yes, inclusion of additional segmentation / Market breakdown is possible subject to data availability and difficulty of survey. However a detailed requirement needs to be shared with our research before giving final confirmation to client.

Receive Sample on Biologics Research: https://www.coherentmarketinsights.com/insight/request-sample/2663

Competitive Analysis:

The research report on Biologics Market evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The report extensively provides the market share, growth, trends and forecasts for the period 2018-2026. The market size in terms of revenue (USD MN) is calculated for the study period along with the details of the factors affecting the market growth (drivers and restraints).

The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved. The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities. The report classifies the market into different segments based on technique, application and end-user. These segments are studied in detail incorporating the market estimates and forecasts at regional and country level. The segment analysis is useful in understanding the growth areas and probable opportunities of the market.

Purchase Copy of This Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/2663

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

#biologics market #biologics market industry #biologics market growth

0 notes

omkeshwari-blog · 5 years ago

Text

Global Elspar Market Market Outlook, Revenue, Trends and Forecasts Research Report 2019-2025

Global Elspar market: Snapshot Market Overview of Elspar Market : The report provides a global analysis of Elspar Market 2019 Report provides Insightful information to the clients enhancing their basic leadership capacity identified. This Report is segmented into Manufactures, Types, Applications, and Regions. The market covers the wide spectrum of the factors governing future growth including drivers, challenges, emerging trends, technology changes, and environmental factors. Erwinia L-Asparaginase is an enzyme, as a medication it is used to treat acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin's lymphoma. It is given by injection into a vein, muscle, or under the skin. A pegylated version is also available.The global Elspar market was xx million US$ in 2018 and is expected to xx million US$ by the end of 2025, growing at a CAGR of xx% between 2019 and 2025. The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels. The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report Request for Sample Report @ https://www.acquiremarketresearch.com/sample-request/80693/ The Elspar market report analyses the growth opportunities as well as the threats to the Elspar market w.r.t Business Tactics, Sales Volume and Latest Developments that are taking place in Elspar Industry. Facts such as the Product launch events, Elspar industry news, growth drivers, challenges and investment scope have been analyzed at depth in Elspar research report. Some of the most prominent Key Vendors: Jazz Pharmaceuticals, Shire, Medac GmbH, Kyowa Hakko Kirin, Qianhong Bio-pharma, Taj Pharmaceuticals, Mingxing Pharma, Exova (SL Pharma), United Biotech Regions covered in the market report: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Applications Segment Analysis: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Other Product Segment Analysis: Escherichia coli, Erwinia Chrysanthemi, Pegylated Grab Your Report at an Impressive Discount! Please click here (with Business Email-Id) @https://www.acquiremarketresearch.com/discount-request/80693/ The study objectives of this report are: • To study and forecast the market size of Elspar market. • To analyze the global key players, SWOT analysis, value and global market share for top players. • To define, describe and forecast the market by type, end use and region. • To analyze and compare the market status and forecast between China and major regions, namely, North America, Europe, France, UK, Asia-Pacific, South America and Middle East and Africa. • To analyze the global key regions market potential and advantage, opportunity and challenge, restraints and risks. • To identify significant trends and factors driving or inhibiting the market growth. • To analyze the opportunities in the market for stakeholders by identifying the high growth segments. • To strategically analyze each submarket with respect to individual growth trend and their contribution to the market • To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market • To strategically profile the key players and comprehensively analyze their growth strategies. Browse the full report Description, TOC and Table of Figure @ https://www.acquiremarketresearch.com/industry-reports/elspar-market/80693/ Our experts and analysts evaluate the vendors in the Elspar market and provide understandings to articulate current and future market trends, innovation, customer expectations and competitive forces. The overviews, SWOT analysis and strategies of each vendor in the market provide understanding about the Elspar market forces and how those can be oppressed to create future opportunities.

#Elspar Elspar Market Future Elspar Market Growth Elspar Sales Market News Acquire Market Research

0 notes

pharmanewstrands-blog · 5 years ago

Text

Cancer Metabolism Based Therapeutics Market, By Drug, Indication - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018–2026

According to the study published in the Journal of Cancer Biology and Therapy, 2013, the controversial discovery of the 20th century by Otto Warburg led to study of metabolic activity in cancerous tissue, which increases the amount of production of lactate from glucose by tenfold under aerobic condition. This has revealed that heterogeneity is developed at cellular level leading to proliferation of cancerous cells due to increased metabolism rate. Cancer metabolism is based on the principle of cancer cells, which alter the metabolism of glucose and glutamine for the synthesis of lipids, nucleotides, fatty acids, and proteins that helps to proliferate cancer cells. It results in inhibition of various metabolic pathways, such as the citric acid cycle, glucose, mitochondrial respiration, and glutamine utilization. Limited options of cancer metabolism targeting therapies are expected provide potential opportunities for development of novel cancer metabolism-based therapeutics in the near future.

Request A Sample Copy: http://bit.ly/2FnRjLg

Targeting cancer metabolism condition represents a potential opportunity to develop novel drugs to treat multiple cancer types, which is expected to boost the growth of cancer metabolism-based therapeutics market

Rafael pharmaceuticals, introduced a breakthrough drug, CPI-613 in 2017, which is an anti-cancer compound - Altered Energy Metabolic Directed (AEMD) drug specifically designed to target the mitochondrial tricarboxylic acid (TCA) cycle in cancer metabolism. CPI-613 is being evaluated in clinical trial phase II. The Food and Drug Administration (FDA) designated CPI-613 as an orphan drug for the treatment of pancreatic cancer, acute myeloid leukemia (AML), and Myelodysplastic syndromes (MDS). Rafael intends to apply CPI-613, as an orphan drug designation for MYC amplified lymphoma/Burkitt lymphoma and T-cell lymphoma in near future. Therefore, offering orphan drug to the cancer patients would help to gain more value and share for cancer metabolism based therapeutics market.

Celgene Corporation and Agios Pharmaceutical announced that the Food and Drug Administration (FDA) approved New Drug Application (NDA) for enasidenib – oral form, in August 2017. The FDA granted the NDA, as a priority review for cancer metabolism drug. Enasidenib is a first-in-class drug, which is expected to target relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 2 (IDH2) mutation.

Calithera Biosciences, Inc. announced novel cancer therapeutic drug named CB–839 in 2017. The FDA granted CB-839 as a Fast Track designation drug with the combination of everolimus for the treatment of metastatic renal cell carcinoma. CB-839 is being evaluated in clinical trials phase I and II for the treatment of solid tumors non-small cell lung cancer, renal cell carcinoma, melanoma, and triple negative breast cancer.

Increasing incidence of cancer is expected to fuel the growth of cancer metabolism based therapeutics market

According to National Cancer Institute, in the U.S, approximately 21,380 (1.3%) new cases and approximately 10,590 deaths due to acute myeloid leukemia (AML) are estimated in 2017. An increasing number of cancer cases among people is expected to generate demand for new therapeutics, which helps to target cancer metabolism condition, in turn fueling the growth of cancer metabolism-based therapeutics market in near future.

The major key players in of cancer metabolism-based therapeutics market include Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca.

Click To Read More On: Cancer Metabolism Based Therapeutics Market

About Coherent Market Insights:

Mr.Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email:[email protected]

#cancer metabolism based therapeutics market cancer metabolism based therapeutics market trends cancer metabolism based therapeutics market g

0 notes

vijaykurane · 4 years ago

Text

Acute Myeloid Leukemia Therapeutics Market Size, Growth and Future Forecasts to 2027

Industry Analysis of the Acute Myeloid Leukemia Therapeutics Market Report 2020-2027

Global Acute Myeloid Leukemia Therapeutics market has been leaning towards the growth curve and contributing to the global economic scenario on the basis of growth rate and revenue. The Global Acute Myeloid Leukemia Therapeutics Market research report provides a detailed explanation to the reader about the fundamentals of the Acute Myeloid Leukemia Therapeutics market, which is inclusive of the business strategies, market demands, key players, and a futuristic outlook of the market.

The research report is inclusive of the impact analysis of the currently unfolding COVID-19 pandemic. The pandemic has affected the economic scenario of the world and brought about dynamic changes in the demands and trends of key segments of the market. The report covers the current and future impact of COVID-19 on the overall market.

Avail the inside scoop of the Sample report @ https://www.reportsanddata.com/sample-enquiry-form/3354

The substantial growth of the Acute Myeloid Leukemia Therapeutics market over the last decade and the current trends and demands point towards its growth in the forecast period (2020-2027). The report covers all the investment opportunities, market dynamics, threats, opportunities, challenges, restraining factors, and technological advancements in the global Acute Myeloid Leukemia Therapeutics market. The cumulative information about crucial segments provides a thorough analysis to the reader that might assist them in achieving expected goals for their business.

Major Players evaluated in the Report:

Ambit Biosciences Corporation, Cephalon, Clavis Pharma, Eisai, Genzyme Corporation, Sunesis Pharmaceuticals, Takeda Pharmaceuticals, Amgen, Celgene, and Sanofi, among others.

For this report, Reports and Data has segmented the Global Acute Myeloid Leukemia Therapeutics Market based on Regimen, Treatment Type, End-user, and Region:

Regimen Outlook (Revenue, USD Billion; 2017-2027)

DC Regimen

AVD Regimen

VCD Regimen

Treatment Type Outlook (Revenue, USD Million; 2017-2027)

Chemotherapy

Radiation therapy

Stem Cell Transplant

Targeted Therapy

End-User Outlook (Revenue, USD Billion; 2017-2027)

Hospital

Retails Drug Stores

Ambulatory Care Centers

Clinics

Market Analysis based on Key Geographical Regions:

The report covers key regions such as North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. The report covers the production, growth, sales, demands, and consumption patterns, and forecast detail.

Get the Entire Market Intelligence Report At @ https://www.reportsanddata.com/report-detail/acute-myeloid-leukemia-therapeutics-market

Key Benefits of the Report:

Clear understanding of the Acute Myeloid Leukemia Therapeutics market and its operations

Industrial chain analysis along with the current and future market trends and opportunities

Current market scenario and forecast estimation up to 2027 to understand the full growth potential of the Acute Myeloid Leukemia Therapeutics industry

In-depth analysis of the factors influencing the growth of the market

Strategic marketing recommendations, key information for market entrants, and expansion plans of other businesses to offer a competitive edge to the reader

Extensive profiling of key competitors along with their business structures, strategies, and business expansion plans.

The report provides a comprehensive analysis of competitive landscape along with detailed analysis of the mergers, acquisitions, joint ventures, partnerships, collaborations, and other strategic alliances. It also provides an extensive analysis of the latest product developments, technological advancement, and advancements research and developments in the global Acute Myeloid Leukemia Therapeutics industry. The study offers forecast estimations up to 2027.

Focal Points of the Report:

· Market Coverage: This section of the report gives a detailed account of the key manufacturers, market segments, product scope, product range, forecast period, and application landscape.

· Executive Summary: This chapter focuses on the market growth rate, significant market drivers and restraints, current market trends, and competitive outlook.

· Regional Analysis: This section delves into the latest import and export trends of the market, production and consumption ratio, the leading market players in each region, and revenue generation.

· Manufacturers’ Portfolio: Complete portfolios of all the local and global manufacturers, along with the SWOT analysis, production value and capacity, product catalogue, and other important details of their businesses, constitute this section of the report.

Moreover, the report covers business strategies of the key market players along with extensive detailing of the competitors, their business expansions, partnerships, and government deals, new product launches, recently adopted technologies, strategic alliances, and manufacturing and production developments. The report also covers regulatory policies and their effects on market dynamics.

Fill all the details to get the Sample Copy of the Report @ Sample URL

Thank you for reading our report. If you have any request for customization, kindly connect with us and our team will assist you and ensure the report is tailored according to your needs.

Related Reports –

1. Digital journal– http://www.digitaljournal.com/pr/4750850?noredir=1

2. Market Watch - https://www.marketwatch.com/press-release/acute-myeloid-leukemia-therapeutics-market-to-reach-usd-356-billion-by-2027-reports-and-data-2020-07-22?mod=mw_quote_news

3. Globe News Wire - https://www.globenewswire.com/news-release/2020/07/22/2066107/0/en/Acute-Myeloid-Leukemia-Therapeutics-Market-To-Reach-USD-3-56-Billion-By-2027-Reports-And-Data.html

John Watson

Head of Business Development

Direct Line: +1-212-710-1370

E-mail:

[email protected]

Reports and Data | Web:

www.reportsanddata.com

#Acute Myeloid Leukemia Therapeutics Market

0 notes

wiseguyreport1222 · 3 years ago

Link

0 notes

vinayakmrfr1998-blog · 4 years ago

Text

Myelodysplastic Syndrome (MDS) Drugs Market Growth and Investment Feasibility By 2025

Global Myelodysplastic Syndrome (MDS) Drugs Market Research Report: Information by Drug Type (Chemotherapy, Immunomodulatory Drugs), Type of Syndrome (Refractory Cytopenia with Multilineage Dysplasia, Refractory Anemia, Refractory Anemia with Excess Blasts, Refractory Anemia with Ringed Sideroblasts, Refractory Cytopenia with Multilineage Dysplasia), Route of Administration (Oral, Parenteral), End-User (Hospitals, Clinics, Ambulatory Surgical Centers) and Region - Global Forecast till 2025

Myelodysplastic syndrome (MDS) are a group of cancers in which blood cells in the bone marrow do not mature making it susceptible to other diseases. When left untreated, MDS can expand to a type of cancer affecting the bone marrow cells known as acute myeloid leukemia (AML). The global myelodysplastic syndrome drugs market report by Market Research Future (MRFR) consists of the various developments in drug discovery, moves by existing players, and other pertinent factors.

Market Overview

The global myelodysplastic syndrome (MDS) drugs market is estimated to reach a significant value by showcasing a CAGR of 10.1% during the forecast period (2018-2023). It stood at USD 1,581.59 million in 2018. Rise in the number of clinical trials for testing the effects of new drugs in combination with chemotherapy can drive the market growth. Approval of decitabine, a product of Lupin Ltd, by the U.S. FDA is an indicator of the acceptance of new drugs by the market.

The rising numbers of the geriatric populace, regulatory approvals, and advocation of clinical trials pertaining to MDS are other major drivers of the global myelodysplastic syndrome drugs market. Improvement of healthcare services by cancer centers and development of novel therapeutics can fuel the market growth successfully till 2023.

But adverse effects of the drugs and risk of infections during blood transfusions can impede the market growth.

Free Report Sample At:

https://www.marketresearchfuture.com/sample_request/8134

Segmentation

The global myelodysplastic syndrome drugs market is segmented by type, type of syndrome, route of administration, and end-user.

By type, it is segmented into immunomodulatory drugs, chemotherapy, and others. The chemotherapy segment is sub-segmented into hypomethylating drugs and conventional drugs. On the other hand, immunomodulatory drugs are further divided into thalidomide and lenalidomide.

By type of syndrome, it is segmented into refractory cytopenia with multilineage dysplasia, refractory anemia with ringed sideroblasts, refractory cytopenia with excess blasts, refractory cytopenia, and others.

By route of administration, it is segmented into parenteral, oral, and others.

By end-user, it is segmented into ambulatory surgical centers, hospitals, clinics, and others. The hospitals segment is expected to contribute the maximum to the global market net earnings owing to the capability of doctors at hospitals for dealing with a large number of MDS patients.

Regional Analysis

The Middle East & Africa (MEA), Europe, Asia Pacific (APAC), and North America are the main regions considered during the compilation of the market report.

The Americas are touted to reign in the top position in the global MDS drugs market till 2023 due to the high prevalence of patients detected with the disease. According to the American Society of Clinical Oncology in 2019, nearly 10,000 patients are detected with MDS annually.

The APAC MDS drugs market is projected to showcase a massive growth rate due to the large wherewithal in research and development activities. Clinical studies are one of the biggest drivers of the market, with one famous study claiming the different types of cancers affecting patients according to their race.

The European region can be a lucrative area for the global myelodysplastic syndrome drugs market due to approvals from regulatory agencies and clinical studies pinpointing the root causes in genotypes of patients in the region.

Competition Outlook

Sandoz, Otsuka America Pharmaceutical Inc., Celgene Europe Limited, Lupin Ltd Corporation, Shilpa Medicare Limited, Celgene Corporation, Johnson & Johnson, Reddy's Laboratories, Inc., Sun Pharmaceutical Industries Inc., and BluePoint Laboratories are prominent names in the global myelodysplastic syndrome drugs market.

Industry News

Onconova Therapeutics Inc has decided to collaborate with Mission Bio for using the latter’s platform for providing breakthrough treatments for MDS. The company plans to use it to study the effects of its targeted therapy, Rigosertib on single-cell DNA analysis.

Browser complete report at:

https://www.marketresearchfuture.com/reports/myelodysplastic-syndrome-drugs-market-8134

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: [email protected]

#Myelodysplastic Syndrome (MDS) Drugs Market #Myelodysplastic Syndrome (MDS) Drugs Market Growth #Myelodysplastic Syndrome (MDS) Drugs Market Share #Myelodysplastic Syndrome (MDS) Drugs Market Size #Myelodysplastic Syndrome (MDS) Drugs Market Trends

0 notes

deafeningmusicfury · 4 years ago

Text

Platelet Aggregation Devices Market Size, Growth Opportunities, Trends by Manufacturers, Regions, Application & Forecast to 2027

Request for a sample copy of this research report @ https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market/request-for-sample

Complete Summary with TOC Available @ https://www.polarismarketresearch.com/industry-analysis/platelet-aggregation-devices-market

Purchase This Report @: https://www.polarismarketresearch.com/checkouts/6581

Polaris Market research has segmented the vascular access devices market report on the basis of product, application, end-use and region

Platelet Aggregation Devices Type Outlook (Revenue – USD Million, 2016 – 2027)

Systems

Reagents

Consumables and Accessories

Platelet Aggregation Devices Application Outlook (Revenue – USD Million, 2016 – 2027)

Research Applications

Clinical Applications

Others

Platelet Aggregation Devices End-Use Outlook (Revenue – USD Million, 2016 – 2027)

Standalone Hospitals

Diagnostic Laboratories

Research and Academic Institutes

Blood Banks

Other End Users

Platelet Aggregation Devices Regional Outlook (Revenue – USD Million, 2016 – 2027)

U.S.

Canada

France

Germany

Italy

Spain

Netherlands

Austria

China

India

Japan

Malaysia

South Korea

Indonesia

Mexico

Brazil

Argentina

UAE

Saudi Arabia

Israel

South Africa

Read More@ https://www.medgadget.com/2020/07/platelet-aggregation-devices-market-size-worth-1556-8-million-by-2027-cagr-20-1-exclusive-study-by-polaris-market-research.html

About Polaris Market Research

Polaris Market Research

Phone: 1–646–568–9980

Email: [email protected]

Web: www.polarismarketresearch.com

#Platelet Aggregation Devices Market #Platelet Aggregation Devices Market share #Platelet Aggregation Devices Market size

0 notes

marketreasearch · 5 years ago

Text

Hemato Oncology Testing Market Analysis 2019 Top companies are F. Hoffmann-La Roche Ltd, Abbott Laboratories, QIAGEN, Thermo Fisher Scientific Inc., Illumina, Inc

Hemato Oncology Testing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growat a CAGR of 14.10% in the above-mentioned forecast period. Increasing cases of leukemia and increasing demand for personalized medicines will create new opportunities for this market in the forecast period of 2020- 2027.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hemato-oncology-testing-market

The major players covered in the hemato oncology testing market report are F. Hoffmann-La Roche Ltd, Abbott Laboratories, QIAGEN, Thermo Fisher Scientific Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., MolecularMD, ArcherDx, Inc., ARUP Laboratories., Invivoscribe, Inc., CORE Diagnostics, Genoptix, Inc., GenPath, NeoGenomics Laboratories, Inc., Siemens AG, among other players domestic and global. Market Share data is available for Global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Market Analysis and Insights:

Hemotology is that route of medicine which deals with the treatment, causes, and other problems associated with the blood. On the other hand, oncology is connected with the study of the treatment, diagnosis, and other problem associated with cancer. Hematolo-oncology is the method used to treat diseases and blood disorders and cancers.

Increasing cases of hematologic cancer and growing awareness about the advanced treatment therapies among population will drive the market growth. Rising cases of myeloma cancers and lymphoma will also affect the market positively. Leukemia patients are constantly keeping track on the status of minimal residual disease which is also expected to affect the market positively. Favourable reimbursement policy on the hemato oncology testing products will also enhance the market growth. On the other hand, rising collaboration between manufacturer, increasing conferences on personalized medicines, and growing demand for advanced treatment options will also create new opportunities for the hemato oncology testing market in the forecast period of 2020- 2027.

This hemato oncology testing market report provides details of market share, new developments, product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief our team will help you create a revenue impact solution to achieve your desired goal.

Global Hemato Oncology Testing Market By Product & Services (Services, Assay Kits), Cancer Type (Leukemia, Lymphoma, Other Cancers), Technology (PCR, IHS, NGS, Cytogenetics, Other), End- Users (Clinical Laboratories, Hospitals, Academic & Research Institutes, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa), Market Share Forecast to 2027

Grab Your Report at an Impressive 30% Discount! Please click Here@https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hemato-oncology-testing-market

Global Hemato Oncology Testing Market Scope and Market Size

Hemato oncology testing market is segmented of the basis of product & services, cancer type, technology and end use. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on product & services, hemato oncology testing market is segmented into services, and assay kits.

On the basis of cancer type, the hemato oncology testing market is classified into leukemia, lymphoma, and other cancers. Leukemia is further divided into acute myeloid leukemia, acute lymphocytic leukemia, and other leukemia. Lymphoma is segmented into non-hodgkin lymphoma and hodgkin lymphoma.

The hemato oncology testing market is also segmented on the basis of technology as PCR, IHS, NGS, cytogenetics, and other.

The global hemato oncology testing market has also been segmented based on the end use into clinical laboratories, hospitals, academic & research institutes, and others

Hemato Oncology Testing Market Country Level Analysis

Hemato oncology testing market is analysed and market size insights and trends are provided product & services, cancer type, technology and end use as referenced above.

The countries covered in the hemato oncology testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific in the Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa as a part of Middle East and Africa, Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hemato oncology testing market due to favourable reimbursement policy for hemato oncology testing products while Asia-Pacific is expected to grow at the highest growth rate in the forecast period 2020 to 2027 due to increasing patient population.

The country section of the hemato oncology testing market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Table Of Content: Hemato Oncology Testing Market

Part 01: Executive Summary Part 02: Scope Of The Report Part 03: Hemato Oncology Testing Market Part 04: Global Hemato Oncology Testing Market Sizing Part 05: Global Hemato Oncology Testing Market Segmentation By Product Part 06: Five Forces Analysis Part 07: Customer Landscape Part 08: Geographic Landscape Part 09: Decision Framework Part 10: Drivers And Challenges Part 11: Market Trends Part 12: Vendor Landscape Part 13: Vendor Analysis

Continue. .

For Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-hemato-oncology-testing-market

Healthcare Infrastructure growth Installed base and New Technology Penetration

Hemato oncology testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for hemato oncology testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hemato oncology testing market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Hemato Oncology Testing Market Share Analysis

Hemato oncology testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to hemato oncology testing market

The report provides insights on the following points:

Learn about the market strategies that are being adopted by your competitors and leading organizations

Market Penetration: Comprehensive information on the product portfolios of the top players in the trocars market

To gain insightful analyses of the market and have a comprehensive understanding of the “Hemato Oncology Testing Market ” and its commercial landscape

To understand the future outlook and prospects for Hemato Oncology Testing Market analysis and forecast 2019-2026.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the market

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: [email protected]

0 notes

myabhijitr · 5 years ago

Text

Biologics Market Size, Share, Outlook, Analysis, and Forecast 2018-2026

Biological products include a wide range of products such as vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Many biologics are produced using recombinant DNA technology. Biologics are the best used drugs for genetic disorders. New technologies, novel therapies are emerging for the manufacturing of new biologics which holds a prominent future for biologics market. Biologics are widely used to prevent, treat, diagnose, or cure a variety of diseases including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases. Biologics are also used in treatment of rare diseases in children like for treatment of Batten disease, cerliponase alfa was approved in 2017 for the first time by U.S. Food and Drug Administration (FDA).

Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/2663

The biologics market size is expected to boost owing to the increasing product pipeline from different companies like Merck and Co., Pfizer, Glaxosmithkline. Pfizer has a strong product pipeline for 2019 of biologics, biosimilars, vaccines and small molecules. 35 products are in phase 1, 28 are in phase 2 and 26 are in phase 3 and 11 products are in the process of registration. Total 100 products are in trial phase. Most recent approval by Pfizer is DAURISMO (glasdegib) in U.S. for adult patients with newly-diagnosed acute myeloid leukemia for whom intensive chemotherapy is not an option.

North America holds dominant position in the global biologics market, owing to presence of major pharmaceutical and biopharmaceutical companies in the U.S. such as AbbVie, Amgen, Biogen Idec, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson and Johnson, Merck and Co., Novartis, Pfizer, and Sanofi with a great product portfolio in biologics. In 2018, 59 novel drugs and biologics were approved in by FDA’s Center for Drug Evaluation and Research and were launched in the U.S.

Asia Pacific is anticipated to witness significant growth in biologics market size because of production and manufacturing of biosimilar products of biologics. A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. For instance, Indian biopharmaceutical company Biocon Ltd., launched two biosimilars CANMAb (trastuzumab) and Krabeva (bevacizumab) in India in year 2014 and 2017 respectively for treatment of several types of cancer.

More Information On This Report: https://www.coherentmarketinsights.com/ongoing-insight/biologics-market-2663

#biologics market #biologics market size #biologics market outlook

0 notes